Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current Vascular Pharmacology

• Publication date

  2012-08-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157016112801784503PMID 22272912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Immunosuppressive Agents on Long-Term Survival of Renal Transplant Recipients

  2012cited by this paper
• Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin

  2011cited by this paper
• Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis.

  2011cited by this paper
• Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

  2011cited by this paper
• Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study

  2011cited by this paper
• Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment.

  2011cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database.

  2010cited by this paper
• Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.

  2010cited by this paper
• Mycophenolate Mofetil in the Treatment of Adults with Advanced Rheumatoid Arthritis

  2010cited by this paper
• Cardiac involvement in systemic rheumatic diseases: An update.

  2010cited by this paper
• Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.

  2010cited by this paper
• Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases

  2010cited by this paper
• Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis

  2010cited by this paper
• Cyclosporin A and atherosclerosis--cellular pathways in atherogenesis.

  2010cited by this paper
• Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins

  2010cited by this paper
• Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?

  2009cited by this paper
• Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study

  2008cited by this paper
• Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis

  2008cited by this paper
• Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis

  2008cited by this paper
• Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

  2008cited by this paper
• Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups.

  2008cited by this paper
• Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.

  2008cited by this paper
• The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.

  2008cited by this paper
• Statin treatment for rheumatoid arthritis: a promising novel indication

  2008cited by this paper
• Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.

  2008cited by this paper
• Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages.

  2008cited by this paper
• The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs

  2008cited by this paper
• Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.

  2008cited by this paper
• Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

  2008cited by this paper
• The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006

  2008cited by this paper
• Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.

  2008cited by this paper
• Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis

  2007cited by this paper
• All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

  2007cited by this paper
• Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

  2007cited by this paper
• Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.

  2007cited by this paper
• A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.

  2007cited by this paper
• The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists

  2007cited by this paper
• What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology

  2007cited by this paper
• Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.

  2007cited by this paper
• Celecoxib for the prevention of colorectal adenomatous polyps.

  2006cited by this paper
• Patterns of cardiovascular risk in rheumatoid arthritis

  2006cited by this paper
• Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved.

  2006cited by this paper
• Antirheumatic drug use and the risk of acute myocardial infarction.

  2006cited by this paper
• Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.

  2006cited by this paper
• Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

  2006cited by this paper
• Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?

  2006cited by this paper
• Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.

  2006cited by this paper
• Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?

  2006cited by this paper
• Antimalarial agents: closing the gate on Toll-like receptors?

  2006cited by this paper
• Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis.

  2006cited by this paper
• Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study

  2006cited by this paper
• Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study

  2006cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey.

  2005cited by this paper
• Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

  2005cited by this paper
• Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.

  2005cited by this paper
• Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease

  2004cited by this paper
• Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

  2004cited by this paper
• Effect of glucocorticoids on the arteries in rheumatoid arthritis.

  2004cited by this paper
• Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

  2003cited by this paper
• Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

  2003cited by this paper
• Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis.

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.

  2003cited by this paper
• Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study

  2002cited by this paper
• Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.

  2002cited by this paper
• Inflammation in atherosclerosis

  2002cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Mechanism of action for leflunomide in rheumatoid arthritis.

  1999cited by this paper
• Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset.

  1999cited by this paper
• No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.

  1998cited by this paper
• Lipid abnormalities in stable liver transplant recipients – effects of cyclosporin, tacrolimus, and steroids

  1998cited by this paper
• Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

  1997cited by this paper
• Dyslipidemia and rheumatoid arthritis.

  1997cited by this paper
• Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

  1997cited by this paper
• Innovative treatment approaches for rheumatoid arthritis. Combination therapy.

  1995cited by this paper
• Corticosteroids: do they damage the cardiovascular system?

  1994cited by this paper
• Dyslipoproteinemia in the course of active rheumatoid arthritis.

  1992cited by this paper
• [T-helper cell subsets in patients with inflammatory rheumatic diseases undergoing immunosuppressive therapy].

  1991cited by this paper

• Cambios en la función endotelial vascular de pacientes con artritis reumatoidea en tratamiento

  2020cites this paper
• Time course of changes in lipid profile measures in patients with early psoriatic arthritis during adalimumab therapy

  2019cites this paper
• RISK OF CARDIOVASCULAR DISEASE IN PATIENTS OF RHEUMATOID ARTHRITIS (RA) PRESENTING IN A TERTIARY CARE HOSPITAL OF PAKISTAN

  2018cites this paper
• Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use.

  2016cites this paper
• Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis

  2016cites this paper
• Deciphering Cardiovascular Disease in Systemic Inflammatory Diseases Using Advanced Magnetic Resonance Imaging

  2015cites this paper
• Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches

  2015cites this paper
• Edema and fibrosis imaging by cardiovascular magnetic resonance: how can the experience of Cardiology be best utilized in rheumatological practice?

  2014cites this paper
• Rapid crystal dissolution in gout: is it feasible and advisable?

  2014cites this paper
• Why currently used diagnostic techniques for heart failure in rheumatoid arthritis are not enough: the challenge of cardiovascular magnetic resonance imaging.

  2014cites this paper
• Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases

  2014cites this paper
• Reactivity against the Five Domains of β 2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

  2014cites this paper
• The effects on markers of cellular stress and RAGE splicing in cellular models and in subjects receiving dietary CLA supplementation

  2012cites this paper
• Atherosclerosis and Rheumatoid Arthritis: More Than a Simple Association

  2012cites this paper